Rock Springs Capital Management LP lifted its position in Bicara Therapeutics Inc. (NASDAQ:BCAX – Free Report) by 14.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 489,095 shares of the company’s stock after buying an additional 60,000 shares during the quarter. Rock Springs Capital Management LP’s holdings in Bicara Therapeutics were worth $9,728,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Quantinno Capital Management LP grew its stake in Bicara Therapeutics by 16.1% during the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after acquiring an additional 2,447 shares in the last quarter. Orbimed Advisors LLC boosted its holdings in Bicara Therapeutics by 219.1% in the 1st quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock valued at $13,273,000 after purchasing an additional 458,200 shares during the period. Siren L.L.C. boosted its holdings in Bicara Therapeutics by 11.2% in the 1st quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after purchasing an additional 586,001 shares during the period. Walleye Capital LLC bought a new position in Bicara Therapeutics in the 1st quarter valued at $2,148,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Bicara Therapeutics by 166.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 109,261 shares of the company’s stock valued at $2,170,000 after purchasing an additional 68,327 shares in the last quarter.
Insider Buying and Selling
In other Bicara Therapeutics news, CEO Claire Mazumdar sold 10,000 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $28.42, for a total transaction of $284,200.00. Following the sale, the chief executive officer owned 362,152 shares in the company, valued at $10,292,359.84. This trade represents a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total value of $817,641.72. Following the sale, the chief operating officer owned 182,177 shares in the company, valued at $5,279,489.46. The trade was a 13.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 88,450 shares of company stock worth $2,366,675. Corporate insiders own 13.80% of the company’s stock.
Bicara Therapeutics Price Performance
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, research analysts anticipate that Bicara Therapeutics Inc. will post -3.42 earnings per share for the current year.
Analyst Ratings Changes
Several research firms have recently weighed in on BCAX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Guggenheim assumed coverage on Bicara Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $42.00 price objective for the company. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. Wedbush restated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Finally, Wells Fargo & Company upped their target price on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $30.27.
View Our Latest Stock Analysis on Bicara Therapeutics
Bicara Therapeutics Company Profile
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Read More
- Five stocks we like better than Bicara Therapeutics
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Want to see what other hedge funds are holding BCAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bicara Therapeutics Inc. (NASDAQ:BCAX – Free Report).
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
